Psychotherapeutic Augmentation of Brain Stimulation Effects (PAUSE)
Primary Purpose
Depression Chronic, Depression, Unipolar, Treatment Resistant Depression
Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
EffEKTiv 2.0 group CBT as continuation treatment after ECT in depressed patients
Treatment as usual
Sponsored by
About this trial
This is an interventional treatment trial for Depression Chronic
Eligibility Criteria
Inclusion Criteria:
- treated with ECT for major depression
Exclusion Criteria:
- severe comorbid personality disorders
- principal diagnosis other than depression
Sites / Locations
- Charité
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Group CBT
Treatment as Usual
Arm Description
15-week group CBT with a focus on improvement of social interactions by cognitive re-modelling and role plays. Patients may simultaneously receive continuation ECT and/or individual psychotherapy and/or take anti-depressive medication.
Patients may receive continuation ECT and/or individual psychotherapy and/or take anti-depressive medication.
Outcomes
Primary Outcome Measures
Clinican-Rated Depressive Symptoms at treatment end
MADRS
Clinican-Rated Depressive Symptoms at follow-up
MADRS
Secondary Outcome Measures
Quality of life at follow-up
WHOQL-Bref
Emotion regulation capacities at follow-up
Cognitive Emotion Regulation Questionnaire
Self-Reported Depressive Symptoms at treatment end
BDI
Self-Reported Depressive Symptoms at follow up
BDI
Full Information
NCT ID
NCT04159285
First Posted
August 1, 2019
Last Updated
August 2, 2021
Sponsor
Charite University, Berlin, Germany
1. Study Identification
Unique Protocol Identification Number
NCT04159285
Brief Title
Psychotherapeutic Augmentation of Brain Stimulation Effects
Acronym
PAUSE
Official Title
Augmenting and Sustaining Electroconvulsive Therapy (ECT) Treatment Effects by Group Cognitive Behavioural Therapy (CBT) in Unipolar Depressed Patients
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
January 5, 2019 (Actual)
Primary Completion Date
May 1, 2021 (Actual)
Study Completion Date
June 15, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Charite University, Berlin, Germany
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aims to investigate effectiveness and feasability of a 15-week group psychotherapeutic intervention as continuation treatment after electroconvulsive therapy in severely depressed patients. Feasibility and acceptance of the half-open manualized CBT intervention are assessed. Depressive symptoms, quality of life and emotion regulation skills will be assessed before ECT treatment, before and after the 15-week group CBT intervention and at a 6 months follow-up after treatment end and compared to depressed patients treated with ECT who did not partake in group CBT. Moreover, patients will attend two indidivual pre-group sessions with one of the group therapist and one individual post-group session
Detailed Description
While Electroconvulsive therapy (ECT) is a highly effective anti-depressant treatment, a relevant number of patients experience recurrence of depressive episodes within 6 months.
One previous study suggested that ECT treatment effects can be effectively sustained by group CBT (Cognitive Behavioral Therapy, Brakemeier et a. 2014). This previous implementation used a closed CBT-group set-up that implicated a longer waiting period for patients after finishing the acute ECT and did not investigate whether patients who did not respond to ECT could sufficiently profit from group CBT. In order to suit the complex needs of patients in a natural clinical setting, the present study aims to investigate the feasibility and effectiveness of a half-open continuous group CBT (named EffECtive 2.0) as continuation treatment for all ECT patients regardless of remission status after ECT.
This prospective study will recruit a total of 30 patients who concluded treatment with right-unilateral ultra-brief ECT for depression. Patients self-allocate to the group that is offered in addition to continuation treatment as usual (TAU, e.g. pharmacological treatment, continuation ECT, individual psychotherapy). ECT completers who choose not to partake in the group for practical concerns or lack of interest and receive treatment as usual are recruited as a control group.
The primary outcome measure is the change depression severity, measured with the Montgomery-Åsberg Depression Rating Scale (MADRS). Secondary outcomes are quality of life assessed with the short-version of the WHO quality of life questionnaire (WHOQOL-Bref) and emotion regulation as assessed with cognitive emotion regulation questionnaire (CERQ). These measures will be assessed before, during, immediately after acute ECT and six and 12 months into continuation therapy.
It is hypothesized that a group CBT as add-on treatment to TAU will lead to more favorable outcomes concerning depression severity, quality of life and emotion regulation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression Chronic, Depression, Unipolar, Treatment Resistant Depression
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group CBT
Arm Type
Experimental
Arm Description
15-week group CBT with a focus on improvement of social interactions by cognitive re-modelling and role plays. Patients may simultaneously receive continuation ECT and/or individual psychotherapy and/or take anti-depressive medication.
Arm Title
Treatment as Usual
Arm Type
Experimental
Arm Description
Patients may receive continuation ECT and/or individual psychotherapy and/or take anti-depressive medication.
Intervention Type
Behavioral
Intervention Name(s)
EffEKTiv 2.0 group CBT as continuation treatment after ECT in depressed patients
Intervention Description
Group CBT with a maximum number of 8 participants. Group is half-open allowing a starting date right after completion of acute ECT treatment. Patients participate for 15 sessions, which are framed by 2 individual sessions before joining the group and one individual session at treatment end.
Intervention Type
Other
Intervention Name(s)
Treatment as usual
Intervention Description
Can include continuation ECT, psychopharmacological treatment, individual psychotherapy
Primary Outcome Measure Information:
Title
Clinican-Rated Depressive Symptoms at treatment end
Description
MADRS
Time Frame
End of group therapy treatment (~6 months after ECT treatment)
Title
Clinican-Rated Depressive Symptoms at follow-up
Description
MADRS
Time Frame
6 months after end of group therapy
Secondary Outcome Measure Information:
Title
Quality of life at follow-up
Description
WHOQL-Bref
Time Frame
6 months after end of group therapy
Title
Emotion regulation capacities at follow-up
Description
Cognitive Emotion Regulation Questionnaire
Time Frame
6 months after end of group therapy
Title
Self-Reported Depressive Symptoms at treatment end
Description
BDI
Time Frame
End of group therapy treatment (~6 months after ECT treatment)
Title
Self-Reported Depressive Symptoms at follow up
Description
BDI
Time Frame
6 months after end of group therapy
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
treated with ECT for major depression
Exclusion Criteria:
severe comorbid personality disorders
principal diagnosis other than depression
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simone Grimm, Prof. Dr.
Organizational Affiliation
Charite Universitaetsmedizin
Official's Role
Principal Investigator
Facility Information:
Facility Name
Charité
City
Berlin
ZIP/Postal Code
12203
Country
Germany
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
24462229
Citation
Brakemeier EL, Merkl A, Wilbertz G, Quante A, Regen F, Buhrsch N, van Hall F, Kischkel E, Danker-Hopfe H, Anghelescu I, Heuser I, Kathmann N, Bajbouj M. Cognitive-behavioral therapy as continuation treatment to sustain response after electroconvulsive therapy in depression: a randomized controlled trial. Biol Psychiatry. 2014 Aug 1;76(3):194-202. doi: 10.1016/j.biopsych.2013.11.030. Epub 2013 Dec 12. Erratum In: Biol Psychiatry. 2014 Sep 1;76(5):430.
Results Reference
background
Learn more about this trial
Psychotherapeutic Augmentation of Brain Stimulation Effects
We'll reach out to this number within 24 hrs